Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En gennemførlighedsundersøgelse for at evaluere sikkerheden af ​​TheraSphere Glioblastoma (GBM)-enheden hos patienter med tilbagevendende GBM (FRONTIER)

29. oktober 2026 opdateret af: Boston Scientific Corporation

FRONTIER: En gennemførlighedsundersøgelse for at evaluere sikkerheden af ​​TheRaSphere GliOblastoma (GBM)-enheden i PATIENTER med tilbagevendende GBM

The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Glioblastoma (GBM) is a highly aggressive brain cancer with a grave prognosis, resulting in <7% of patients surviving to five years post-diagnosis. External beam radiotherapy (EBRT) is currently a mainstay treatment for GBM; however, the dose delivered is limited by side effects. The targeted radiotherapy of the TheraSphere GBM Y-90 Glass Microsphere System (TheraSphere GBM) has promising potential to provide GBM patients with reduced side effects compared to external beam radiotherapy as well as a more effective treatment for this catastrophic disease.

The TheraSphere GBM device utilized in the FRONTIER trial is an yttrium-90 (Y-90) glass microsphere therapy for selective internal radiation therapy (endovascular radiotherapy) in recurrent GBM patients. The TheraSphere GBM treatment utilizes intra-arterial delivery and takes advantage of blood flow and direct tumor delivery. Treatment can be delivered by specific placement of a catheter close to the tumor through known angiographic techniques currently utilized by neuro-endovascular or interventional radiology physicians. Angiographic evaluation prior to treatment allows identification of tumor feeding arteries and definition of the treatment volume. TheraSphere GBM could achieve a high tumor response rate based on delivery of a tumor absorbed dose that is not currently possible with EBRT.

In consideration of the potential benefit of a more localized, targeted treatment with a reduced side effect profile compared to other treatment options, and the potential impact on patients' quality of life for this devastating disease, this First-in-Human Early Feasibility Study (EFS) of the TheraSphere GBM Y-90 Glass Microsphere System for the treatment of recurrent GBM is being conducted.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

36

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35294
        • Trukket tilbage
        • University of Alabama Birmingham
    • California
      • San Diego, California, Forenede Stater, 92103
        • Rekruttering
        • University of California San Diego
        • Ledende efterforsker:
          • Zachary Berman, MD
        • Kontakt:
      • San Francisco, California, Forenede Stater, 94143
        • Rekruttering
        • University of California San Francisco
        • Ledende efterforsker:
          • Nicholas Butowski, MD
        • Kontakt:
    • Florida
      • Jacksonville, Florida, Forenede Stater, 32224
        • Rekruttering
        • Mayo Jacksonville
        • Ledende efterforsker:
          • Alfredo Quinones-Hinojosa, MD
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287
        • Trukket tilbage
        • Johns Hopkins Interventional Radiology Center
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63130
        • Rekruttering
        • Washington University School of Medicine
        • Kontakt:
        • Ledende efterforsker:
          • Arindam Chatterjee, M.D.
    • New York
      • New York, New York, Forenede Stater, 10075
        • Rekruttering
        • Lenox Hill Hospital
        • Kontakt:
        • Ledende efterforsker:
          • John Boockvar, MD
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • MD Anderson Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Stephen Chen, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Subject is 18 years or older and has signed and dated the trial informed consent form (ICF)

  2. Life expectancy ≥ 12 weeks

  3. Subject is willing and able to comply with the trial testing, procedures, and follow-up schedule

  4. History of a histologically confirmed diagnosis of glioblastoma per 2021 WHO criteria

  5. Have radiographic evidence of tumor progression/recurrence with measurable disease (≥ 1 cm to ≤ 5cm bidirectional diameters) by contrast-enhancement on MRI, according to RANO criteria

  6. Prior surgery and treatment with combination of radiotherapy and chemotherapy ± Tumor Treating Fields (Optune®)

  7. Prior cranial radiation dose < 66 Gy

  8. WHO performance status ≤ 2

  9. The interval since completion of cranial radiotherapy must be > 6 months, unless there is tissue confirmation of tumor recurrence/progression outside the previous radiation treatment field, in which case the interval since completion of cranial radiation must be at least 12 weeks

  10. Interval since last systemic therapy until presumed date of intervention ≥ 1 cycle or ≥ 2 biological half-lives, i.e.

    1. ≥ 4 weeks since last dose of temozolomide
    2. ≥ 6 weeks since last dose of lomustine or other nitrosourea
    3. ≥ 2 weeks since last dose of a small molecule targeted agent (Tyrosine Kinase Inhibitor or similar)
    4. ≥ 6 weeks from last dose of last intravenous bevacizumab infusion, or other antibody-based VEGF therapy
  11. If receiving steroids, patient should be on a stable or decreasing dose equivalent to dexamethasone ≤ 6 mg/d, for at least 7 days prior to registration

  12. Have adequate organ and bone marrow function within 14 days prior to registration, as defined below:

    1. INR ≤ 1.2 (in absence of anticoagulation)
    2. Platelets ≥ 100,000/L
    3. Creatinine ≤1.5 mg/dL
    4. Absolute Neutrophil Count ≥1.5 x 10^9/L
    5. Hemoglobin ≥9.0 g/dL
  13. Have a negative pregnancy test within 14 days prior to registration on study (for FOCBP, female of child-bearing potential)

  14. Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active must be using, or agree to use, a medically acceptable method of birth control as confirmed by the investigator

  15. Angiographic Mapping Inclusion Criteria:

    1. Accessible neurovascular anatomy that allows for safe microcatheter placement (up to two locations) to infuse TheraSphere GBM to treat all of the T1 enhancing component of target lesion confirmed by neuro-interventional team.
    2. Total treatment volume is ≤ 150cc as determined by multidisciplinary team.
  16. Additional Inclusion Criteria:

    1. Group A: perfused volume encompasses the non-dominant hemisphere and non-eloquent regions of the brain
    2. Group B: perfused volume encompasses the non-dominant hemisphere and eloquent regions of the brain
    3. Group C: perfused volume encompasses the dominant hemisphere and non-eloquent regions of the brain
    4. Group D: perfused volume encompasses the dominant hemisphere and eloquent regions of the brain

Exclusion Criteria:

  1. Have bilateral gadolinium enhancing disease, tumor located in the posterior fossa, tumor involving critical subcortical structures (thalamus/hypothalamus, midbrain, brainstem, corticospinal tract, internal capsule, cerebral peduncle), tumor approximating or invading the brainstem and/or optic chiasma, leptomeningeal disease, or extracranial metastatic disease

  2. Have received more than 1 course of prior cranial radiotherapy (EBRT)

  3. Have received radiosurgery, brachytherapy, or hypofractionated radiotherapy

  4. Have received more than 2 systemic treatment protocols (lines of treatment), not including maintenance temozolomide

  5. Have received prior intra-arterial cerebral infusion therapy

  6. Have received more than 2 surgical GBM-related procedures

  7. Have received prior thoracic radiation therapy

  8. Are at increased risk of wound dehiscence by the discretion of the investigators (e.g. brain surgery within the last 3 months, poor skin condition, and/or previously infected surgical field or any other condition that is of increased infectious risk in the opinion of the neurosurgeon)

  9. Have uncontrolled epilepsy

  10. Have severe and/or insufficiently controlled intercurrent illness; patients with the following are not eligible:

    1. Hypertension grade 3 or higher without adequate control on medications
    2. Symptomatic or unstable cardiac disease, known to have right-to-left shunts, or severe pulmonary hypertension (pulmonary artery pressure > 90 mmHg)
    3. Pulmonary insufficiency (arterial oxygen pressure (Pa,O2) of < 60 mmHg, or oxygen saturation (Sa,O2) of < 90%) as measured by fingertip pulse oximeter
    4. Ongoing or active bacterial or viral infection requiring systemic treatment (including HIV)
    5. Pneumonitis
    6. Psychiatric illness/social situations that would limit compliance with study requirements
    7. Peripheral Neuropathy ≥ grade 1
    8. Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety, study endpoints or longevity
  11. Are currently pregnant or breast feeding (unless patient agrees to stop breastfeeding)

  12. Patients with a history of an active other malignancy within 1 year prior to registration. NOTE: Exceptions to this requirement include adequately treated non-melanoma skin cancer or lentigo maligna or carcinoma in situ without evidence of disease, or recurrent glioblastoma

  13. Patients with a history of ischemic cerebral disease and/or at risk of cerebral herniation

  14. Medical contraindication to undergo contrast-enhanced magnetic resonance imaging (MRI)

  15. Known history of hypersensitivity reactions to iodinated and/or gadolinium-based contrast

  16. Subject has received any other investigational agents within 4 weeks of treatment, or is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the Boston Scientific study team)

  17. Angiographic Mapping Exclusion Criteria: Patients with significant vascular disease, significant AV shunting, or anatomic tortuosity on MR/CT Angiogram precluding safe or feasible vascular access

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment Group A

Subjects in which the perfused volume encompasses the non-dominant hemisphere and non-eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.

Single treatment of TheraSphere GBM device

Andre navne:
  • TheraSphere™ GBM Y-90 glasmikrokugler (TheraSphere GBM)
Eksperimentel: Treatment Group B

Subjects in which the perfused volume encompasses the non-dominant hemisphere and eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.

Single treatment of TheraSphere GBM device

Andre navne:
  • TheraSphere™ GBM Y-90 glasmikrokugler (TheraSphere GBM)
Eksperimentel: Treatment Group C

Subjects in which the perfused volume encompasses the dominant hemisphere and non-eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.

Single treatment of TheraSphere GBM device

Andre navne:
  • TheraSphere™ GBM Y-90 glasmikrokugler (TheraSphere GBM)
Eksperimentel: Treatment Group D

Subjects in which the perfused volume encompasses the dominant hemisphere and eloquent regions of the brain. The projected radiation absorbed dose to the treatment volume is 40 Gy ±10%.

Single treatment of TheraSphere GBM device

Andre navne:
  • TheraSphere™ GBM Y-90 glasmikrokugler (TheraSphere GBM)

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Antallet af grad 3-5 ikke-hæmatologiske toksiciteter
Tidsramme: 30 dage efter indeksprocedure
30 dage efter indeksprocedure
Antallet af ≥ grad 3 CNS-toksiciteter relateret til ikke-målembolisering
Tidsramme: 30 dage efter indeksprocedure
30 dage efter indeksprocedure
Forekomst af symptomatisk hjernestrålingsnekrose, der kræver medicinsk eller kirurgisk indgreb og bekræftet af patologi
Tidsramme: 30 dage efter indeksprocedure
30 dage efter indeksprocedure
Antallet af grad 4 neutropeni-hændelser, der varer ved i mere end 5 dage
Tidsramme: 30 dage efter indeksprocedure
30 dage efter indeksprocedure
Antallet af grad 4 febril neutropeni
Tidsramme: 30 dage efter indeksprocedure
30 dage efter indeksprocedure
Antallet af grad 4 trombocytopeni eller grad 3 trombocytopeni med blødning
Tidsramme: 30 dage efter indeksprocedure
30 dage efter indeksprocedure

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Hyppighed af eventuelle behandlingsrelaterede bivirkninger og behandlingsrelaterede alvorlige bivirkninger (ikke inklusive foruddefinerede begrænsende toksiciteter) fra den første patient, der blev indskrevet til studiets afslutning.
Tidsramme: Tilmelding gennem 6 måneder efter indeksprocedure
Tilmelding gennem 6 måneder efter indeksprocedure
Objektiv responsrate* (ORR) fra den første patient, der blev indskrevet til studiets afslutning
Tidsramme: Tilmelding gennem 6 måneder efter indeksprocedure
Tilmelding gennem 6 måneder efter indeksprocedure
Progressionsfri overlevelse* (PFS) fra den første patient, der blev indskrevet til studiets afslutning
Tidsramme: Tilmelding gennem 6 måneder efter indeksprocedure
Tilmelding gennem 6 måneder efter indeksprocedure
Samlet overlevelse (OS) fra den første patient, der blev indskrevet til studiets afslutning
Tidsramme: Tilmelding gennem 6 måneder efter indeksprocedure
Tilmelding gennem 6 måneder efter indeksprocedure
Teknisk succes/gennemførlighed af Therasphere GBM - evne til at levere den projicerede stråling absorberede dosis (+/- 20%) til det perfunderede volumen for alle patienter, der er behandlet med enheden. Vurderet fra præ-screening gennem PET-CT/MR af levering af levering af Device.
Tidsramme: Pre-screening gennem levering af PET-CT/MR af enheder.
Pre-screening gennem levering af PET-CT/MR af enheder.
Change in post-treatment neurological function as assessed by the National Institute of Health Stroke Scale (NIHSS).
Tidsramme: Enrollment through 6 months post index procedure

The NIHSS is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment.

Enrollment through 6 months post index procedure
Change in post-treatment neurological function as assessed by the modified Rankin Scale (mRS).
Tidsramme: Enrollment through 6 months post index procedure

The mRS measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability on a scale from 0 (no symptoms at all) to 6 (death).

Enrollment through 6 months post index procedure

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Riad Salem, M.D., Northwestern University
  • Ledende efterforsker: Roger Stupp, M.D., Northwestern University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. juli 2022

Primær færdiggørelse (Anslået)

31. januar 2027

Studieafslutning (Anslået)

30. juni 2027

Datoer for studieregistrering

Først indsendt

10. marts 2022

Først indsendt, der opfyldte QC-kriterier

29. marts 2022

Først opslået (Faktiske)

31. marts 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. oktober 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

29. oktober 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • S2478

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .